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Abstract
Background: MicroRNAs (miRNAs) are a class of short non-coding RNA that play important roles in disease processes in
animals and are present in a highly stable cell-free form in body fluids. Here, we examine the capacity of host and parasite
miRNAs to serve as tissue or serum biomarkers of Schistosoma mansoni infection.
Methods/Principal Findings: We used Exiqon miRNA microarrays to profile miRNA expression in the livers of mice infected
with S. mansoni at 7 weeks post-infection. Thirty-three mouse miRNAs were differentially expressed in infected compared to
naı¨ve mice (.2 fold change, p,0.05) including miR-199a-3p, miR-199a-5p, miR-214 and miR-21, which have previously been
associated with liver fibrosis in other settings. Five of the mouse miRNAs were also significantly elevated in serum by twelve
weeks post-infection. Sequencing of small RNAs from serum confirmed the presence of these miRNAs and further revealed
eleven parasite-derived miRNAs that were detectable by eight weeks post infection. Analysis of host and parasite miRNA
abundance by qRT-PCR was extended to serum of patients from low and high infection sites in Zimbabwe and Uganda. The
host-derived miRNAs failed to distinguish uninfected from infected individuals. However, analysis of three of the parasite-
derived miRNAs (miR-277, miR-3479-3p and bantam) could detect infected individuals from low and high infection intensity
sites with specificity/sensitivity values of 89%/80% and 80%/90%, respectively.
Conclusions: This work identifies parasite-derived miRNAs as novel markers of S. mansoni infection in both mice and
humans, with the potential to be used with existing techniques to improve S. mansoni diagnosis. In contrast, although host
miRNAs are differentially expressed in the liver during infection their abundance levels in serum are variable in human
patients and may be useful in cases of extreme pathology but likely hold limited value for detecting prevalence of infection.
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Introduction
Helminths are parasitic worms that infect a third of the world’s
population and cause a diverse range of health consequences leading to
significant social and economical burdens [1,2]. Schistosomiasis is a
chronic disease caused by blood flukes of the genus Schistosoma that
affects more than 200 million people worldwide and is second only to
malaria as the most important lethal human parasitic disease in tropical
and subtropical regions. Schistosomiasis is predominantly caused by
hepatic S. mansoni and urogenital S. haematobium [3]. It is estimated that
the mortality rates due to haematemesis (S. mansoni) and renal failure (S.
haematobium) are around 130,000 and 150,000 per year respectively [4].
In addition, schistosomiasis is associated with anaemia, diarrhoea,
under nutrition, chronic pain and exercise intolerance, which are
estimated to contribute to 0.02–0.15 disability-adjusted life-years
(DALY) [5].
Diagnosis of schistosome infection is crucial for patient manage-
ment, evaluation of treatment efficiency, monitoring of disease
transmission and success of control strategies, as recommended by
the World Health Organization [6]. In the field, S. mansoni and other
intestinal schistosomes are currently diagnosed through the
detection of the parasite eggs in stool specimens using microscopic
techniques such as Kato-Katz or ether-concentration [7]. While
these techniques are relatively simple, inexpensive and specific, their
major drawbacks include poor sensitivity in detecting low-intensity
infections (for example, in children), their inability to detect pre-
patent or single sex infection and their failure to detect infection in
individuals where eggs are trapped in tissues and not excreted [8].
Available antibody-based assays are useful for diagnosis in some
cases (e.g. foreign travellers) but they cannot differentiate past and
active infection and can also cross-react with antigens from other
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helminths [9]. These assays therefore do not offer a definitive
diagnosis in schistosome-endemic areas. Recent studies have shown
success with point-of-care tests for Schistosoma circulating cathodic
and anodic antigens (CCA and CAA, respectively) in serum and
urine, which decrease rapidly after chemotherapy [8,10,11,
12,13,14] and these are now being further developed for use in
the field [15]. Detection of schistosome DNA in urine and stool
samples or plasma by the polymerase chain reaction (PCR) method
is another strategy for routine diagnosis of infection that has shown
promising results [16,17,18,19,20]. Here we examine whether
microRNAs (miRNAs), which are extremely stable in serum and
detectable by quantitative reverse transcription PCR (qRT-PCR)
could provide an additional diagnostic tool for S. mansoni infection.
miRNAs are a class of naturally occurring small non-coding
RNA produced from animal, plant and viral genomes [21]. They
are incorporated into the RNA-induced silencing complex (RISC)
and function by binding to messenger RNAs (mRNAs) and
inhibiting translation and/or causing mRNA destabilization [22].
Depending on the genes they target, miRNAs have diverse
functions inside cells, from regulation of developmental program-
ming to viral-host interactions [23,24,25]. In the last 5 years,
reports have shown that miRNAs circulate in serum in a cell-free
form and many cell types secrete miRNAs through encapsulation
within exosomes or in association with specific proteins [26,27].
These extracellular RNAs have been implicated in cell-to-cell
communication in a range of systems [28,29], and have been
shown to be extremely stable in body fluids [27,30]. They have
received extensive attention for their promise as biomarkers of
disease, including cancer [31,32,33]. Extracellular miRNAs have
also been shown to be altered in human serum and/or plasma in
infection settings, including hepatitis C and hepatitis B infections
[34,35] as well as during pulmonary tuberculosis [36]. A recent
report has also identified miRNAs derived from rice in human
serum [37], sparking interest in foreign RNA in body fluids and its
diagnostic potential.
Here we investigate the potential of miRNAs to act as tissue and
serum biomarkers of experimental mouse and natural human S.
mansoni infection. We demonstrate that several host miRNAs are
dysregulated in the liver of mice during S. mansoni infection, but do
not serve as reliable serum biomarkers of infection in humans. In
contrast, we identify at least three parasite-derived miRNAs in the
serum of mice infected with S. mansoni that are also detected in
human patients and can distinguish ‘egg-negative’ from ‘egg-
positive’ individuals with high specificity and sensitivity. We
anticipate that parasite-derived miRNAs may provide a general
platform for specific and non-invasive detection of active helminth
infection.
Methods
Animals and S. mansoni infection
For miRNA array analysis of liver and Illumina sequencing of
serum in experiment 1, 8–10 week old C57BL/6 mice were left
uninfected or infected percutaneously with ,180 S. mansoni
cercariae, weighed regularly, and euthanized 7 weeks post
infection. For the 12-week time course, 8–10 week old C57BL/6
mice were left uninfected or infected percutaneously with ,80
cercariae, weighed regularly, and euthanized at 4, 6, 8 and 12
weeks post infection.
Collection of blood and serum
Whole blood was drawn from mice by cardiac puncture. The
needle was removed before emptying the syringe to avoid
haemolysis and blood was allowed to sit for 1 h at RT to clot.
Serum was separated by centrifugation at 2500 g for 15 min at
4uC, and the supernatant was collected into a new tube and spun
at 10,000 g for 1 min to remove remaining cells. The resultant
supernatant was transferred into a new tube and stored at 220uC
prior to RNA extraction.
Human serum samples
Human serum was screened retrospectively from samples
obtained from schistosome endemic areas in Zimbabwe and
Uganda. The study group included in this investigation (Zim-
babwe) was part of a larger study on the molecular immunoepi-
demiology of human schistosomiasis (carried out between
November 1999 and March 2000) and had not been included in
the National Schistosome Control Programme and therefore had
not received treatment for schistosomiasis or other helminth
infections. After collection of all samples, all participants were
offered anti-helminthic treatment with the recommended dose of
praziquantel (40 mg/kg of body weight). The selection of samples
for screening here was based on availability of sufficient serum for
miRNA analysis, and comprised five ‘egg positive’ individuals with
an average egg per gram in stool (epg) = 108, range: 39-277 and
nine ‘egg-negative’ individuals (Table 1). According to the WHO’s
classification, Zimbabwe has high to moderate levels of S.
haemobium infection (prevalence ranging from 10% to greater than
70%) but low S. mansoni prevalence (less than 10%). The selection
of serum for screening from Piida (Uganda) participants was based
on availability of sufficient material and comprised twenty
individuals infected with S. mansoni with an average epg = 1117
(range: 105-4030) and ten egg-negative individuals. The study
group included in this investigation were part of a larger study
carried out in Butiaba village, adjacent to Lake Albert, Masindi
district, Uganda in 1996, described further in [38]. The cohort
had moderate to high S. mansoni infection intensities and
prevalence of 91%. After collection of stool and serum samples
all the study participants, irrespective of the infection status,
received 2 doses of praziquantel, 40 mg/kg of body weight, 6
Author Summary
Schistosomiasis is a chronic disease caused by blood flukes
that affects over 200 million people worldwide, of which
90% live in Sub-Saharan Africa. In the field setting
schistosomiasis caused by S. mansoni is diagnosed by
detection of parasite eggs in stool samples using micro-
scopic techniques. Here we investigate the potential of
microRNAs (miRNAs), a class of short noncoding RNAs, to
act as biomarkers of S. mansoni infection. We have
identified a specific subset of murine miRNAs whose
expression is significantly altered in the liver between 6–12
weeks post infection. However their abundance in serum is
not significantly different between naı¨ve and S. mansoni-
infected mice until twelve weeks post infection and they
do not display consistent differential abundance in the
serum of infected versus uninfected humans. In contrast,
three parasite-derived miRNAs (miR-277, bantam and miR-
3479-3p) were detected in the serum of infected mice and
human patients and the combined detection of these
miRNAs could distinguish S. mansoni infected from
uninfected individuals from low and high infection
intensity areas with 89%/80% or 80%/90% specificity/
sensitivity, respectively. These results demonstrate that
miRNAs of parasite origin are a new class of serum
biomarker for detecting S. mansoni and likely other
helminth infections.
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weeks apart. Efficacy of chemotherapy was assessed 6 weeks after
each treatment.
Ethics statement
Animal experiments were conducted under a Project License
granted by the Home Office (United Kingdom), reference 60/
4104, in accordance with local guidelines and approved by the
Ethical Review Committee of the University of Edinburgh.
For the human serum samples collected in Chiredzi, permission
to conduct the work in this province was obtained from the
Provincial Medical Director. Ethical approval was received from
the Medical Research Council of Zimbabwe (MRCZ). Only
compliant participants were recruited into the study and they were
free to drop out at any point during the study. At the beginning of
the study, participants and their parents/guardians (in case of
children) had the aims and procedures of the project explained
fully in the local language, Shona, and oral consent (as was
customary) was obtained from participants and parents/guardian
before parasitology and blood samples were obtained. For the
samples collected in Piida, ethical clearance was obtained from the
Uganda National Council of Science and Technology (ethics
committee for Vector Control Division, Ugandan Ministry of
Health). The aims and procedures were explained to the local
community at the start of the study and oral consent was obtained
from all adults and from the parents/legal guardians of all children
under 15 who were willing to participate. Due to cultural reasons
and low levels of literacy, oral consent is deemed acceptable by the
Ugandan Ministry of Health and was approved by the Uganda
National Council of Science and Technology. Upon oral consent
participants were enrolled in the study with a written record of
their name, age, sex and case number, this served as both the
record of oral consent and enrolment record.
Parasitology and serum sample collection and processing
Participants in the Zimbabwe study were checked for both
urogenital and intestinal schistosomiasis and for inclusion in this
analysis had to be free of any soil-transmitted helminths and also
free of S. haematobium infection to avoid cross reactivity between
different helminth parasites. For the analysis of urogenital
schistosome infection (S. haematobium) participants submitted three
urine and three stool samples (over four consecutive days). 10 ml
of each sample received was processed on the day of collection by
a urine filtration method [39]. Stool samples were prepared and
examined on the day of collection using the Kato-Katz faecal
smear for detection of S. mansoni eggs and soil transmitted
helminths; this was carried out by trained and experienced
technical staff from the National Institute of Health Research [40].
A single slide for microscopic examination was prepared from
each urine and stool sample. Serum was prepared from 10 ml
venous blood collected from study participants, frozen at 220uC
and afterwards stored at 280uC. Samples were transported frozen
to Edinburgh and stored at 280uC prior to serological assays.
Participants in the Ugandan study had duplicate 50 mg Kato-
Katz slides prepared from 3 consecutive stool samples for
detection of S. mansoni eggs, expressed as mean epg; this was
carried out by trained and experienced technical staff from the
Vector Control division at the Ministry of Health in Uganda.
Serum was prepared from 10 ml venous blood samples, frozen at
220uC and transported to Cambridge for storage at 280uC prior
to serological assays.
Mouse serum RNA extraction
For the 12-week time course experiment, total RNA was
extracted from serum using the miRVana PARIS extraction kit
(Ambion), according to the manufacturer’s protocol. In brief,
100 ml of serum was thawed on ice, mixed with an equal volume of
26Denaturing Solution and kept on ice for 10 min. Samples were
extracted with an equal volume of acid-phenol chloroform,
vortexed for 30 s and centrifuged for 10 min at 10,000 g at RT.
The aqueous phase was mixed with 1.25 volumes of 100% ethanol
and added to the mirVana PARIS column. The column was
washed and RNA eluted in 100 ml of 0.1 mM EDTA. RNA
samples were stored at 220uC prior to further analysis. Extracted
RNA was quantified by Qubit (Invitrogen).
Table 1. Top miRNAs dysregulated in the liver at 7 weeks post S. mansoni infection as determined by microarray analysis and
showing results obtained by qRT-PCR (microarray: p,0.05, Fold change $2, qRT-PCR: t-test).
Up regulated miRNA
miRNA P value Log2 (S.mansoni infected/Naı¨ve ratio) PCR Fold Change PCR P value
miR-199-5p 0.0002 10.1 5.76 ,0.0001
miR-199-3p 0.0001 6.4 5.7 ,0.0001
miR-744 0.0002 5.3 1.2 NS
miR-214 0.0001 4.6 5.42 ,0.0001
miR-210 0.0001 3.9 4.58 0.0001
miR-21 0.002 3.5 4.15 ,0.0001
Down regulated miRNA
miRNA P value Log2 (S.mansoni infected/Naı¨ve ratio) PCR Fold Change PCR P value
miR-151-5p 0.024 212.9 21.42 0.0359
miR-9 0.031 22.3 1.9 NS
miR-365 0.007 22.2 24.24 ,0.0001
miR-192 0.006 22.2 23.35 ,0.0001
miR-194 0.024 22.0 23.32 ,0.0001
miR-122 0.028 22.0 23.2 ,0.0001
doi:10.1371/journal.pntd.0002701.t001
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Human serum RNA extraction
Due to small volumes and low amounts of RNA in available
human serum samples the extraction protocol was adjusted to
result in more concentrated RNA. To do this, 50 ml of serum was
thawed on ice, mixed with 50 ml of ddH2O and 100 ml of 26
Denaturing Solution (as supplied in the miRVana Paris kit) and
kept on ice for 10 min. Samples were spiked with 10 fmoles of a
synthetic RNA, Spike1: 59-UGCUGAAUGCGUAGCUAUA-
AGC-39 (IDT) and extracted with an equal volume of acid-phenol
chloroform, vortexed for 30 s and centrifuged for 10 min at
10,000 g at RT. The aqueous phase was mixed with 1/10 volume
of 3M sodium acetate, 10 mg of GlycoBlue (Ambion) and an equal
volume of isopropanol. Samples were allowed to precipitate
overnight at 220uC and were then centrifuged at .10,000 g at
4uC. Pellets were washed twice with 75% ethanol, air-dried and
then resuspended in 25 ml of 0.1 mM EDTA. The total RNA
concentration was below the limit of detection based on Qubit
(Invitrogen).
Liver RNA extraction
Liver tissue was immersed in RNA Later Solution (Ambion)
overnight at 4uC prior to extraction using TRIzol Reagent
(Invitrogen) according to the manufacturer’s protocol. RNA was
quantified by NanoDrop and integrity assessed by 10% PAGE or
Bioanalyzer 2100. All RNA samples used in the microarray
analysis had RIN .8.
Reverse transcription & PCR
For reverse transcription of mouse serum samples, a fixed
amount of extracted RNA (1.5 ng) was used as an input and 0.1
fmoles of a synthetic RNA, Spike2: 59-CGUAUCGAGUGAU-
GUCACGUA-39, was added at the RT step for normalization.
For human serum samples, where the total RNA concentration
was below the detection limit, a fixed volume of RNA (5 ml),
corresponding to 10 ml of extracted serum, was used as the input
and Spike1 (added at the time of purification) was used for
normalization. For reverse transcription of RNA extracted from
liver, 200 ng of total RNA was used in each reaction. Reverse
transcription reactions were performed using the miScript System
(Qiagen) according to the manufacturer’s protocol. PCR was
carried out with SYBR green real-time PCR assays (Qiagen) and
miScript primers to detect mouse and human miRNAs, according
to the manufacturer’s protocol (Qiagen). Primers for S. mansoni-
specific miRNAs and the synthetic spikes were used at 200 nM
final concentration and were purchased from Invitrogen: miR-
277, 59-TAAATGCATTTTCTGGCCCG-39, miR-2162-3p, 59-
TATTATGCAACGTTTCACTCT-39, miR-3479-3p, 59-TATT-
GCACTAACCTTCGCCTTG-39, bantam, 59- TGAGATCGC-
GATTAAAGCTGGT-39, miR-2a-3p, 59-TCACAGCCAGTAT-
TGATGAAC-39, miR-71a-3p, 59- TGAAAGACGATGGTAGT-
GAGAT-39, sma-miR-n1, 59-AACTCAGTGGCCTATCGGT-
39, sma-miR-n2, 59-TCAGCTGTGTTCATGTCTTCGA-39,
sma-miR-n3, 59- TGGCGCTTAGTAGAATGTCACCG-39,
Spike1, 59-TGCTGAATGCGTAGCTATAAGC-39, Spike2, 59-
CGTATCGAGTGATGTCACGTA-39. Data were collected on a
Light Cycler 480 System (Roche) with the following temperature
profile: pre-denaturation 15 min at 95uC followed by 50 cycles of
denaturation for 15 s at 95uC, annealing for 30 s at 55uC,
elongation for 30 s at 70uC. The efficiencies of pre-optimized
miScript host miRNA probes (Qiagen) were measured from
standard curves and ranged between 93–100% and the efficiency
of custom probes ranged from 87–97%; both displayed homog-
enous melting curves and amplification products of the expected
size, as described in [41], which were examined here by 6% TBE
PAGE (data not shown). Two technical replicates were carried out
for each biological replicate. Nuclease free water was used as a
non-template control.
miRNA array
For the array analysis, 1 mg of total RNA was labelled using the
Hy3 power labeling kit (Exiqon) and hybridized to codelink slides
printed with the miRCury 8.1 probe set as described elsewhere
[42]. Hybridization and washing were carried out following the
manufacturer’s protocols (Exiqon). Background signal was sub-
tracted from foreground signal and data were transformed to log-2
scale. Between-array normalization was carried out using global
array percentiles (matching median of each array); triplicate
probes were represented by the median for each array. Empirical
Bayes moderated t statistic (eBayes) was used to test the null
hypothesis of ‘‘no differential expression’’ between uninfected
(n = 3) and infected (n = 3) liver samples. Since this array was only
used as a filter for further validation, the p values were not
adjusted for multiple testing. The Exiqon 8.1 arrays contained 384
probes specific for mouse miRNAs.
qRT-PCR data analysis
For analysis of miRNAs in liver samples, the relative fold change
between naı¨ve and infected samples was calculated using the
22DDCt method [43], normalized to miR-16; values for infected
mice were compared to values for age-matched naı¨ve controls and
the median value for naı¨ve mice was set to 1 for the purpose of
calculating fold change. For serum miRNA data analysis, Ct
values were ‘‘median-normalized’’ to synthetic RNA spike oligos
as described previously [27]: relative change was calculated as
22Ctn, where Ctn stands for normalized Ct values. The spike-in
sequences did not match any known miRNA in miRBase and the
primers for detecting these did not yield signals in serum by qRT-
PCR, indicating that they do not cross-hybridize with mouse or
human small RNAs (data not shown). Fold change was calculated
as the ratio of the relative change value of the sample compared to
an average of the relative change values of uninfected samples. For
the cumulative analysis of miRNAs, the arithmetic mean of fold
changes for miR-277, miR-3479-3p and bantam were used.
Statistical analysis of qRT-PCR data and receiver operator
characteristic (ROC) curve analysis (95% confidence intervals) was
performed with GraphPad Prism (Version 6) software. Two-way
ANOVA followed by a Sidak multiple comparison test was used to
calculate statistical differences for the mouse miRNA time course
data from serum and liver. For the parasite miRNA serum time
course, one-way ANOVA followed by Holm-Sidak multiple
comparison was used. For analysis of the human serum samples,
the Man-Whitney test was used and p-values of ,0.05 were
considered statistically significant. The measurement of miRNA
levels by qRT-PCR was carried out by a trained doctoral student
who was not blinded to the results of the infection status of each
sample. Of the samples available for screening, none were
excluded from the analysis.
Illumina sequencing
For small RNA sequencing in experiment 1, total RNA was
extracted from serum of 8 pooled S. mansoni-infected mice (Wk 7,
180 cercariae) and 8 uninfected age matched controls (400 ml total
volume) according to the miRVana PARIS protocol (as described
above). The small RNAs were size selected by 15% PAGE and
prepared according to the Illumina small RNA Sample Prepara-
tion Kit version 1.5 and sequenced on the GAIIX. For small RNA
sequencing in experiment 2, total RNA was extracted from serum
of 3 pooled S. mansoni infected mice (Wk 8, 80 cercariae) and 3
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uninfected age matched controls (300 ml total volume) according
to the miRVana PARIS protocol. The library was prepared
according to the TruSeq Small RNA protocol (without size-
selecting small RNA) and sequenced on the HiSeq2.
Raw reads were obtained in fastq format and 39 adapters
trimmed using cutadapt, requiring at least a 6 bp match to the
adapter sequence and a quality threshold of 20. Only reads that
contained the adapter were retained; reads were subsequently
collapsed on primary fasta sequence and only reads present at $2
copies were analyzed. Trimmed, collapsed reads $17 bp were
then aligned to mouse (MM9) or S. mansoni genomes (V5.0) using
BOWTIE version 0.12.5, requiring a perfect match to the full
length of the sequence. Reads that mapped to either genome were
then BLASTN aligned against the RFAM database [BLASTN
parameters: -max_target_seqs 1 -outfmt ‘6 std qseq sseq’ -task
blastn -word_size 6 -dust no] and categorized according to
matches to Rfam class (e.g. rRNA, tRNA, etc.). Mouse reads
without rfam similarities (other than miRNAs) were aligned to
mature miRNAs in miRBase version 19. Some trimmed miRNA
reads aligned to more than one family member: the assignment of
these ambiguous reads is designated with ‘‘X’’ in Table S3. RNAs
that aligned to the S. mansoni genome and did not show RFAM
similarities were passed to mirDeep2.0.0.5 using platyhelminth
miRNAs from miRBase 19 as guides (Table S4); reads mapping to
known miRNAs from miRBase were identified regardless of
miRdeep score, for prediction of novel miRNAs a cut-off value of
0 was used for reporting in Table 1.
Results
Specific host miRNAs are significantly dysregulated in the
liver of mice at 7 weeks post S. mansoni infection
miRNAs are dysregulated in most disease contexts and play
important roles in mediating how cells respond to insult and
infection (reviewed in [44]). Approximately 4–6 weeks after S.
mansoni infection, mature female parasites produce eggs, some of
which are carried by the blood-flow to the liver where they
become trapped [45]. The host immune response induced by the
presence of the egg antigens leads to the formation of granulo-
matous lesions, which are composed of immune cells and collagen
fibres [46] and result in fibrosis and associated pathology. In order
to identify miRNAs associated with S. mansoni-induced liver
pathology, and to prioritise candidates for further screening as
biomarkers, we first compared expression profiles of miRNAs in
livers of naı¨ve mice or mice that were infected with S. mansoni at a
high dose (,180 cercariae). Tissues were collected at 7 weeks post
infection, at which time substantial granulomas were observed
(data not shown). A total of 33 mouse miRNAs were differentially
expressed: 26 miRNAs were up-regulated and 7 miRNAs were
down-regulated in infected mice, based on a fold change cut-off of
$2 and p value cut off ,0.05 (Table S1, Fig. S1). The miRNAs
that displayed the largest differential expression included miR-
199a and miR-214, which are known to be altered in liver fibrosis
caused by hepatitis C infection or induced by carbon tetrachloride
[47,48]. Among the down regulated miRNAs was the liver-
enriched miR-122, which is dysregulated during hepatitis C
infection, acetaminophen overdose and hepatocellular carcinoma
and is involved in lipid metabolism [49,50].
For validation of the microarray results, the miRNAs that
displayed the largest fold change were quantified by qRT-PCR
and normalized to miR-16 (a total of 6 up-regulated miRNAs and
6 down-regulated miRNAs were examined). Consistent with the
array results, there was an increase in miR-199-5p, miR-199-3p,
miR-214, miR-21, miR-210, and a reduction of miR-192, miR-
194, miR-365, miR-122 and miR-151 in the liver tissue of S.
mansoni infected mice as compared to naı¨ve mice; miR-9 and miR-
744 did not display differential expression and were not analysed
further (Table 1). All of these miRNAs are perfectly conserved in
mouse and human.
Temporal expression analysis of miR-199, miR-214, miR-
21, miR-210, miR-122, miR-192 and miR-194 in the liver
during S. mansoni infection
Between weeks 6 and 12, female parasites continue to produce
,300 eggs per day [51], resulting in an increase in the number of
granulomas in the liver and the development of fibrosis [45]. For
the 10 miRNAs validated to be differentially expressed at 7 weeks
post infection, we next examined their temporal expression
between 4–12 weeks post infection using a lower parasite dose
(80 cercariae). All data from infected mice were compared to age-
matched naive mice. To account for differences in RNA extraction
or qRT-PCR efficiency, the data were normalised to miR-16,
which displayed stable expression in the liver during infection (Fig.
S2). Of the 10 miRNAs examined, all except miR-365 and miR-
151 were differentially expressed between naı¨ve and infected mice
by 6–8 weeks post infection (Fig. 1, Table S2). This timing
correlated with the deposition of eggs in the liver, which were
detected by 6 weeks post infection and increased by 8 and 12
weeks post infection (Fig. S3). Our results suggest that these
cellular miRNAs represent tissue biomarkers of infection that may
play a role in the development and progression of liver fibrosis
induced by S. mansoni egg deposition.
Temporal host miRNA dysregulation in the liver during
infection is not reflected in serum
Several studies in non-helminth systems have shown that liver-
derived miRNAs are detectable in serum and can be used as
biomarkers in disease states [52,53,54,55,56]. We therefore
examined whether the murine miRNAs that are altered in liver
tissue are similarly altered in serum during S. mansoni infection.
qRT-PCR was used to measure miRNA levels in the serum of mice
infected with S. mansoni over the 12 week time course. The
methodology of miRNA analysis in body fluids is not well
standardized, and it is still not clear which small RNAs are
appropriate for normalization [57,58,59,60]. Here we used a
constant amount of total RNA in the reverse transcription reaction.
To account for any variation in qRT-PCR efficiency due to
contaminants, miRNA levels were normalized to a synthetic RNA
oligo (‘‘spike-in’’) that was included at the reverse-transcription step.
The ratio of miRNA levels in infected versus age-matched naı¨ve
mice was quantified at each time point and plotted as fold change
(Fig. 2). Compared to the analysis of liver samples, there is more
variation in the serum miRNA levels between biological replicates.
As shown in Fig. 2, the levels of miR-192, miR-194 and miR-122 in
serum do not change between 4–12 weeks post infection, whereas
five of the miRNAs that are up-regulated in the liver are also
significantly elevated in serum at 12 weeks post infection (p,0.05),
ranging from 2.6 fold (miR-21) to 4.7 fold (miR-214) (Table S2).
These five host miRNAs represent potential serum biomarkers of S.
mansoni infection. However, since their levels do not change until 12
weeks post infection in mice, they may only be useful in cases of
more advanced pathology.
Small RNA sequencing reveals the presence of S.
mansoni-derived miRNAs in the serum of infected mice
Multiple cell types release or secrete miRNAs into the
circulation [59,61] and it is possible that other miRNAs, beyond
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Figure 1. Differential expression of host miRNAs in the livers of mice at 4–12 weeks post infection with S. mansoni. miRNAs were
quantified by qRT-PCR, normalized to miR-16 and fold changes calculated as the ratio of values from infected versus naı¨ve mice (*p,0.05, **p,0.01,
***p,0.001, ****p,0.0001).
doi:10.1371/journal.pntd.0002701.g001
Figure 2. Differential abundance of host miRNAs in mouse serum during S. mansoni infection. miRNAs were quantified by qRT-PCR and
normalized to a synthetic RNA spike-in. Each symbol represents data from one individual mouse. Fold changes are defined as the ratio of abundance
in infected versus naı¨ve serum; the signal from naı¨ve was set as 1. (***p,0.001, ****p,0.0001).
doi:10.1371/journal.pntd.0002701.g002
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those differentially expressed in the liver, might represent
biomarkers of infection. To examine this in an unbiased fashion,
small RNAs from serum of naı¨ve mice or mice infected with S.
mansoni were sequenced using the Illumina platform. Small RNA
libraries were prepared in two independent experiments, using two
different preparation methods (Methods). In both experiments, the
majority of small RNA reads aligned to the mouse genome
(ranging from 63–71%, Table 2). A small percentage of reads
unambiguously aligned to the S. mansoni genome in infected mice
(0.04–0.14%); ,0.01% of reads mapped to the S. mansoni genome
in naı¨ve samples. Interestingly, the majority of reads in all samples
were derived from tRNAs: 92–98% of the reads that mapped to
the mouse genome and 42–100% of reads that mapped to the S.
mansoni draft genome (Table 2). It is important to note, however,
that due to the sequence similarity of the tRNAs between species
and the scope for post-transcriptional editing, we cannot at this
point definitively determine the organism from which these derive.
Only 1–6% of the reads that mapped to the mouse genome were
miRNAs (Table 2, listed in Table S3). There was no correlation
between differences in host miRNA levels in naive and infected
mice from the two experiments (data not shown), this could relate
to the different doses, although it is not possible to derive statistical
conclusions from these data due to low read numbers. A total of 78
and 29 mature miRNAs are known to be encoded by the
trematodes S. japonicum and S. mansoni, respectively [62,63,64,65],
and further miRNAs have been predicted [62]. Analysis of the
reads that mapped to the S. mansoni draft genome using the
miRdeep2 program [66] identified at least 11 miRNAs from
infected samples: 8 of these were positively identified based on
identity to known miRNAs in S. mansoni and/or S. japonicum
(Table 3) [64,65] and 3 are predicted by miRdeep (here named
sma-miR-n1, sma-miR-n2 and sma-miR-n3). The predicted stem-
loop structures for the putative pre-miRNAs are shown in Fig. 3;
since the depth of coverage of S. mansoni reads in this study was
very low and reads did not map to both arms of the hairpin, these
cannot yet be considered prototypical miRNAs. However, sma-
miR-n3 shares a seed site with Schmidtea mediterranea miR-2160 and
was annotated as sma-miR-8437 in a study of S. mansoni miRNAs
published after submission of this manuscript [67]. Additional
analysis of the datasets allowing 1 mismatch to the S. mansoni draft
genome identified one further miRNA from infected but not naı¨ve
serum: miR-277, which is identical to miR-277 in S. japonicum and
Echinococcus granulosus but has a CRT mutation at position 17 in
relation to the S. mansoni draft genome (Table 3). Other reads from
infected samples that aligned to S. mansoni but did not make the
miRdeep2 cut-offs are provided in Table S4. It is possible that
some of these less abundant sequences derive from real miRNAs
but the coverage in these studies is not sufficient to determine this.
S. mansoni miRNAs are present in mouse serum as early
as 8 weeks post infection
To determine the kinetic profile of parasite miRNAs in serum
during S. mansoni infection, qRT-PCR analysis was carried out as
described above, using primers specific for 9 of the 11 parasite
miRNAs. The other 2 miRNAs, sma-miR-10-5p and sma-let-7-3p,
were excluded from analysis because they are highly similar to
homologous mouse miRNAs that are present at .100 fold higher
read frequencies (Table S3). Importantly, most miRNAs in
helminth parasites have evolved after the last common ancestor
with their vertebrate hosts and are therefore distinguishable in
sequence, however several miRNAs are perfectly conserved across
animals or highly similar in sequence [63]. Several of the parasite-
specific probes showed a signal in the serum of naı¨ve mice, which
is presumably due to cross-hybridization with endogenous small
RNAs. In cases where no signal was observed in naı¨ve mice, the
maximum cycle value of 50 was set as background for the purpose
of calculating signal over noise (which we interchange here with
‘‘fold change’’). Six of the nine parasite miRNA probes tested
(miR-277, bantam, miR-3479-3p, miR-2a-3p, miR-n1, miR-n2)
showed a statistically significant signal over noise at 8 or 12 weeks
post infection (Fig. 4, p,0.05); the three miRNAs that were not
reliably detected (miR-n3, miR-71a-3p, miR-2162-3p) were not
analysed further. The average signal over noise ratios for each
probe during the time course of infection are provided in Table S5
and range from 4.2 to .3,000.
Three S. mansoni-derived miRNAs are detected in human
serum and distinguish egg-negative from egg-positive
individuals
Based on the results described above, we extended our analyses to
human patients, using the 6 parasite miRNAs and 5 mouse
miRNAs that displayed differential abundance in serum of infected
compared to naı¨ve mice. Serum samples from two field sites were
examined: an area of high infection in the Piida community of
Uganda and an area of low infection in the Chiredzi community of
Zimbabwe. The high infection samples were collected from mixed-
age participants from Piida diagnosed as S. mansoni infected, termed
‘egg positive’ and compared to volunteers from the same
community with undetectable parasite eggs in the stool, termed
‘egg-negative’. The low infection samples were collected from
children in Chiredzi diagnosed with S. mansoni and compared to age
matched participants with undetectable eggs by standard stool
examination methods. Demographic data of individuals are
provided in Tables 4 and 5. The signal over noise was calculated
as described above, using synthetic spike-ins for normalization.
miR-n1, miR-n2 and miR-2a-3p were below the detection limit
(Ct = 50) in both ‘egg-positive’ and ‘egg-negative’ samples. The 5
host miRNAs were detectable in serum (miR-21, miR-199-3p, miR-
199-5p, miR-210, miR-214) but showed variable abundance and
failed to differentiate ‘egg-positive’ and ‘egg-negative’ participants
(Fig. S4). In contrast, three out of the six parasite miRNAs (bantam,
miR-277 and miR-3479-3p) displayed a significant signal over noise
level in the serum of S. mansoni infected individuals ‘egg-positive’
from both high (Fig. 5A) and low (Fig. 5B) infection endemic areas,
compared to the ‘egg-negative’ participants from the same
communities (p,0.05, Mann – Whitney test). Data presented using
ROC curves show that the single parasite miRNAs discriminated
between S. mansoni ‘egg-negative’ and ‘egg-positive’ with an area
under the curve (AUC) of 0.785, 0.790, 0.768 for bantam, miR-277
and miR-3479-3p, respectively, in the individuals from Uganda
(Fig. 5A) and 0.889, 0.933, 0.911 in the individuals from Zimbabwe
(Fig. 5B). Using optimal cut-off points, this translates to detection of
S. mansoni infected individuals with specificity/sensitivity of 80%/
60%, 80%/70% and 80%/60%, in the patients from Uganda
(Fig. 5A) and specificity/sensitivity of 100%/60%, 89%/80% and
89%/80% respectively in the patients from Zimbabwe (Fig. 5B). A
repeated measurement of the parasite miRNA levels in the same
samples displayed Pearson correlation values between 0.86 to 0.95
and comparable specificity/sensitivity values (Table S6). When
combining the data for all three of the miRNAs into a cumulative
value, the AUC increased to 0.845 and 0.933 for each cohort of
participants. This resulted in improved specificity/sensitivity in
detection for samples from Uganda (80%/90%) using a fold change
cut-off of 1.189 (Fig. 6). This approach is very similar to a recent
report that uses a ‘‘miRNA score’’ based on cumulative normalized
signals of miRNAs [68]; analysis of our data based on cumulative
fold change or cumulative normalized signals yields very similar
results (Fig. S5). These results show that combining data for bantam,
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miR-277 and miR-3479-3p may improve sensitivity of S. mansoni
diagnosis compared to analysis of individual miRNAs.
Discussion
The recent evidence that miRNAs can be released into
circulation from mammalian cells and tissues has stimulated
extensive interest in the potential use of these molecules as non-
invasive biomarkers [31,32,57]. MiRNA-based diagnostics are
being developed for a number of diseases and although qRT-PCR
is the most common detection method at present, there is extensive
interest in improving and diversifying detection technologies,
which may provide more field-friendly tools. Since miRNAs have
been shown to be extremely stable in body fluids [27,30,69], we
anticipate that these nucleic acids could be particularly useful as
diagnostics in field settings where collection and storage conditions
can be difficult to control. Here we find that miRNAs derived from
the helminth parasite S. mansoni are present in infected mouse and
human serum and offer advantages over endogenous miRNAs as
biomarkers of infection. Specifically, we find 9 known miRNAs
Table 2. Small RNA classification in serum of naı¨ve and infected mice.
Illumina Small RNA
(Experiment 1) TruSeq (Experiment 2)
Naı¨ve Infected Naı¨ve Infected
7 weeks 8 weeks
180 cercariae 80 cercariae
Trimmed reads 19,992,215 19,687,439 5,360,110 6,975,834
Mouse genome match 12,864,294 12,771,443 3,786,803 4,621,905
Unambiguous 12,841,090(64.2%) 12,430,681 (63.1%) 3,779,361 (70.5%) 4,613,742 (66.1%)
rRNA 6493 (0.05%) 51173 (0.4%) 377 (0.01%) 6499 (0.14%)
tRNA 12,615,823 (98.2%) 11,464,782 (92.2%) 3,736,007 (98.9%) 4,409,765 (95.6%)
other rfam 7579 (0.06%) 14563 (0.012%) 514 (0.014%) 1758 (0.04%)
miRNA 128,222(1.0%) 772,150 (6.2%) 36,615 (1.0%) 158,069 (3.4%)
Uncharacterized 82973 (0.6%) 128013 (1%) 5848 (0.16%) 37651 (0.8%)
S.mansoni genome match
Unambiguous 1,683 (,0.01%) 27,347(0.14%) 529 (,0.01%) 2,914 (0.04%)
rRNA 272 (16.2%) 2828 (10.3%) 0 182 (6.2%)
tRNA 1,236 (73.4%) 20,191 (73.8%) 529 (100%) 1,231 (42%)
other rfam 52 (3.1%) 117 (0.4%) 0 22 (0.75%)
miRNA 2 (0.12%) 148 (0.54%)1 0 25 (0.9%)
Uncharacterized 121 (7.2%) 4,063 (15%) 0 1,454 (49.9%)
1This does not include 42 reads identical to sja-miR-277 that contain 1 nucleotide mismatch to S. mansoni draft genome.
doi:10.1371/journal.pntd.0002701.t002
Table 3. Parasite-miRNAs in serum of mice infected with S. mansoni identified by deep-sequencing.
Name miRNA sequence (59-39) Precursor Location Reads2
sma-miR-n2 UCAGCUGUGUUCAUGUCUUCGA S_mansoni.SC_0170:285549..285631:- 66
sja-miR-2771 UAAAUGCAUUUUCUGGCCCGUA Inferred from sja-miR-277 in miRBase 42
sma-bantam UGAGAUCGCGAUUAAAGCUGGU S_mansoni.SC_0137:369450..369509:+ 37
sja-miR-2162-3p UAUUAUGCAACGUUUCACUCU S_mansoni.SC_0049:36195..36251:+ 29
sma-miR-3479-3p UAUUGCACUAACCUUCGCCUUG S_mansoni.Chr_4.unplaced.SC_0032:1561293..1561349:- 16
sma-miR-n1 AACUCAGUGGCCUAUCGGU S_mansoni.Chr_1:18109172..18109229:- 9
sma-miR-n3 UGGCGCUUAGUAGAAUGUCACCG S_mansoni.Chr_3:22962153..22962218:+ 7
sma-miR-10-5p AACCCUGUAGACCCGAGUUUGG S_mansoni.Chr_4:19959278..19959336:- 4
sma-miR-2a-3p UCACAGCCAGUAUUGAUGAAC S_mansoni.Chr_W:22875762..22875816:+ 3
sma-let-7-3p3 CAUACAACCGACUGGCUUUCC S_mansoni.Chr_7:5118795..5118860:+ 2
sma-miR-71a-3p UGAAAGACGAUGGUAGUGAGAU S_mansoni.Chr_W:22875670..22875724:+ 2
1The nucleotide which does not match the S. mansoni draft genome is shown in bold;
2Reads in combined infected samples (compared to a combined total of 930,209 mouse miRNAs in the same samples, Table 1);
3The 3p arm of sma-let-7 is not annotated in mirbase.
doi:10.1371/journal.pntd.0002701.t003
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and at least 2 novel putative miRNAs derived from S. mansoni that
are present in the serum of infected mice. The read counts of some
of these are very low (between 2–66 reads per 930,209 mouse
miRNAs reads) and will require further validation with better
coverage. However, we show that three of these miRNAs (bantam,
miR-277, mirR-3479-3p) can be detected in human serum from
schistosome endemic areas. These represent a direct marker for
infection and may also provide an indirect marker for the
pathology induced by infection. Notably, a study published after
submission of this manuscript identified 5 miRNAs derived from
S. japonicum in the plasma of infected rabbits and 3 of these
are identical or homologous to those identified here: bantam,
Figure 4. Detection of parasite-derived miRNAs in mouse serum during S. mansoni infection. miRNAs were quantified by qRT-PCR,
normalized to a synthetic RNA spike-in and fold change calculated as the ratio of abundance in infected serum compared to the background
abundance level detected in naı¨ve serum, which represents the noise in the assay likely derived from cross-hybridization with endogenous small
RNAs (*p,0.05, **p,0.01, ***p,0.001, ****p,0.0001).
doi:10.1371/journal.pntd.0002701.g004
Figure 3. Predicted stem-loop structures of the S. mansoni miRNAs identified in this study. The mature sequence that was identified in
serum is shown in bold.
doi:10.1371/journal.pntd.0002701.g003
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miR-3479-3p and miR-10-5p [70], providing independent vali-
dation for the presence of trematode miRNAs in the serum of
infected animals. Here we demonstrate small RNAs derived from
a helminth parasite are also present in patient serum, and provides
a starting point for developing more field-friendly methods for
their detection. This work also extends a burgeoning area of
research detailing ‘‘foreign’’ small RNAs in body fluids. Zhang et
al., (2012) recently reported that the plant miRNA, miR-168a, is
present in human and animal serum and demonstrated that this
derives from a rice diet [37]. Wang et al., (2012) recently reported
Table 5. Chiredzi study participants.
Characteristic Egg-negative (n=9) Egg-positive (n =5)
Age (range) 10.67 (8–11) 10 (9–11)
Sex (M/F) 6/3 2/3
S.mansoni status (epg &
range)
0 108 (39–277)
doi:10.1371/journal.pntd.0002701.t005
Table 4. Piida study participants.
Characteristic Egg-negative (n =10) Egg-positive (n=20)
Age (range) 33.1 (17–48) 24.2 (7–56)
Sex (F/M) 5/5 9/11
S.mansoni status (epg &
range)
0 1117 (105–4030)
doi:10.1371/journal.pntd.0002701.t004
Figure 5. Discrimination between the S. mansoni infected and uninfected individuals using parasite-specific miRNA detection.
miRNAs were quantified by qRT-PCR, normalized to a synthetic RNA spike-in and fold changes calculated as the ratio of infected to uninfected
(median with interquartile range indicated). Piida- panel A, Chiredzi- panel B. Specificity and sensitivity and ROC curves with AUC are indicated.
(*p,0.05, **p,0.01).
doi:10.1371/journal.pntd.0002701.g005
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that a wide range of exogenous RNAs can be found in human
plasma, including small RNAs derived from bacteria and fungi [71].
From our results is not yet clear whether the miRNAs identified in
serum are actively secreted from the parasite and how they are
stabilized, since serum contains high amounts of RNases [72,73].
From the time course analysis presented here, schistosome-derived
small RNAs were reliably detected in serum by 8 weeks post
infection, after deposition of the eggs in the liver (Fig. 4 and Fig. S4).
At present, we cannot determine whether these RNAs derive from
the adult worms or the eggs; further in vitro and in vivo studies will
shed light on this issue, which is relevant to diagnostic applications,
for example the capacity to detect pre-patent infection.
It is intriguing to think that existence of these miRNAs outside
the parasite has a function, but this is beyond the scope of the
current analysis. Given the short size of miRNAs and the fact that
they do not require perfect complementarity with their targets, one
could predict hundreds of possible targets in the host. Interestingly,
Xue et al. (2008) showed that three of the miRNAs that we find in
serum (sja-bantam, sja-miR-71 and sja-let-7) are expressed during
all the stages of parasite development but are enriched in the
cercariae, suggesting that they may be important during the initial
stages of schistosome infection [65]. The bantam miRNA has been
implicated in regulating organ growth in response to environmen-
tal conditions in Drosophila as well as C. elegans [74,75] but
functional homologues of bantam do not exist in mammals.
An initial objective in this study was to identify host miRNAs that
may be involved in liver pathology associated with S. mansoni
infection and to then determine whether these hold any diagnostic
value. A number of reports have demonstrated an increase in miR-
122 and miR-192 in plasma or serum upon viral infection as well as
chemically induced liver disease [54,56]. However, according to our
analysis, although miR-192, miR-122 and miR-194 were down-
regulated in the liver during infection, their levels in serum did not
change significantly (Fig. 1–2). In contrast, the miRNAs up-
regulated in the liver (miR-199-3p, miR-199-5p, miR-21, miR-214
and miR-210) showed significantly higher levels in mouse serum at
12 weeks post infection (Fig. 2), however these failed to differentiate
S. mansoni infected from uninfected humans (Fig. S4). It should be
noted that in addition to significant liver disease, pulmonary and
intestinal complications can also occur during S. mansoni infection
that could also contribute to serum miRNA levels [45,76]. Related
to this, a possible limitation in the use of endogenous miRNAs as
biomarkers is the fact that their differential abundance in serum can
derive from multiple cell types and can also be attributed to
unrelated conditions [59]. Although the diagnostic value of these
host miRNAs in serum is therefore not obvious, our work provides a
foundation for further research into the functional role of these
miRNAs in S. mansoni pathogenesis. Interestingly, our results do not
overlap with those reported by Han et al., (2013) who examined
changes in host miRNA levels in the liver of BALB/c mice during S.
japonicum infection. We assume this may be due to the very early
time point (10 days post infection) used in their study. Indeed, it is
likely that the host miRNA changes we observe are primarily related
to the liver pathology and/or the immune response initiated by the
parasite eggs trapped in the liver, rather than the initial host
immune response to the schistosomula. Several of the miRNAs we
identify as differentially expressed are already known to be
associated with liver fibrosis or disease in other, non-helminth,
settings [49,50,77,78]. The functional role of the miRNAs in the
pathology induced by S. mansoni infection remains to be determined.
Future work in this area will shed light on the molecular basis of
pathology and may offer innovative new therapeutic strategies.
Importantly, we report here that parasite-derived miRNAs can
be detected in human serum and can distinguish ‘egg-negative’
from ‘egg-positive’ individuals in areas of both low and high
infection intensity. By combining data for miR-277, miR-3479-3p
and bantam we detected infection with a sensitivity of 80–90%
and specificity of 80–89%. We anticipate that this may be
improved further by optimizing isolation protocols, probe design
and more robust methods for normalizing the data, for example to
identify appropriate endogenous small RNAs that could be used as
controls, rather than synthetic spike-ins [79]. The main limitation
of miRNA detection in serum appears to be cross-hybridization of
the probes with endogenous small RNAs, which influences the
signal to noise ratios. In particular, we report the finding that the
majority of small RNAs in mouse serum are derived from tRNAs
Figure 6. Discrimination between the S. mansoni infected and uninfected individuals using the combined data for 3 parasite
miRNAs. Fold-changes (median with interquartile range indicated) and ROC curves for bantam, miR-277 and miR-3479-3p (Piida- panel A, Chiredzi-
panel B) (**p,0.01).
doi:10.1371/journal.pntd.0002701.g006
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(Table 2), consistent with a recent study [80]. It is possible that
depletion of these tRNAs prior to qRT-PCR may improve the
specificity or sensitivity of miRNA detection; this requires further
investigation. In addition, one of the parasite-derived miRNAs
identified by sequencing, miR-2162-3p could not be validated by
qRT-PCR, likely owing to its low GC content (33%). Optimiza-
tion of probe design for the parasite-derived miRNAs may also
greatly increase their diagnostic utility in larger scale studies in
human patients. On this note, the work presented here was
performed on a relatively small number of individuals. Following
further optimization of the extraction methods and probe design to
minimize cross hybridization and sensitivity, larger studies will be
important to assess the full potential of the proposed miRNA
biomarkers, including positive and negative predictive values in
comparison to existing techniques. It will also be of interest to
determine the origin of these parasite-derived miRNAs and
examine their abundance levels in response to treatment. We
anticipate that the parasite miRNAs in serum could complement
or transform existing diagnostic strategies and may serve as a
platform for detecting a range of helminth infections.
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